Möchten Sie immer auf dem neuesten Stand bleiben?

4 July 2023: Vistin Pharma ASA (the “Company”) has on 4 July 2023 sold shares to members of its management team for its long-term incentive plan (LTIP), as approved by the general meeting on the 22...

4 July 2023: Reference is made to the stock exchange release of Vistin Pharma ASA (“Vistin” or the "Company") dated 30 June 2023 at 07:30 hours CEST concerning an offer to buy back shares (the...

30 June 2023: Vistin Pharma ASA (the “Company”) has decided to launch an offer to all shareholders in the Company to buy back up to 250,000 shares in the Company in connection with its Long Term...

Attached is today's presentation held in relation to Vistin Pharma's Capital Markets Day at the Metformin manufacturing plant in Kragerø. Attachment Capital Markets...

Magnus Tolleshaug, Chief Commercial Officer in Vistin Pharma ASA, and a primary insider, has on 31st of May 2023 purchased 15.000 shares in Vistin Pharma ASA at an average price of NOK 24,01 per...

Ferncliff Listed DAI AS has on 30 May 2023 purchased 250,000 shares in Vistin Pharma ASA at NOK 23.12 per share. After the transaction Ferncliff Listed DAI AS has a holding of 1,034,280 shares,...

Oslo, Norway, 22 May 2023 Vistin Pharma ASA (OSE: VISTIN): Please find attached the minutes from the Annual General Meeting held today, on the 22 May 2023. All matters were resolved as proposed...

In relation to the Annual General Meeting in Vistin Pharma ASA on the 22nd of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total of 3 905 611 shares...

Vistin Pharma will host a Capital Markets Day (CMD) for all interested parties on the 14th of June at its production plant in Stuttlidalen 4 at Fikkjebakke in Kragerø. The invitation is attached. ...

Oslo, Norway, 28 April 2023 Vistin Pharma ASA (OSE: VISTIN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 22 May at 13:00 CEST. A physical Annual...